User menu

Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults.

Bibliographic reference Sokal, Etienne ; Hoppenbrouwers, Karel ; Vandermeulen, Corinne ; Moutschen, Michel ; Léonard, Philippe ; et. al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults.. In: The Journal of Infectious Diseases, Vol. 196, no. 12, p. 1749-1753 (2007)
Permanent URL http://hdl.handle.net/2078.1/11250